<!DOCTYPE html>
<html lang="en">
<head>
<meta name="robots" content="noindex, nofollow">
<meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1">
<title>Institutional Background — Judicialização da Saúde</title>
<style>
  :root {
    --bg: #f8f9fa; --card: #fff; --fg: #1a1a1a; --muted: #666;
    --border: #dee2e6; --accent: #0d6efd; --accent2: #198754;
  }
  * { box-sizing: border-box; margin: 0; padding: 0; }
  body {
    font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, sans-serif;
    background: var(--bg); color: var(--fg); line-height: 1.5;
  }

  main {
    padding: 1.5rem 2rem 3rem; max-width: 900px; margin: 0 auto;
  }

  /* Markdown body styles */
  .md-body { font-size: .92rem; line-height: 1.7; color: #1f2328; }

  .md-body h1 { font-size: 1.5rem; font-weight: 600; margin: 1.8rem 0 .8rem; padding-bottom: .3rem; border-bottom: 1px solid var(--border); }
  .md-body h2 { font-size: 1.25rem; font-weight: 600; margin: 1.6rem 0 .6rem; padding-bottom: .25rem; border-bottom: 1px solid var(--border); }
  .md-body h3 { font-size: 1.05rem; font-weight: 600; margin: 1.3rem 0 .5rem; }
  .md-body h4 { font-size: .95rem; font-weight: 600; margin: 1.1rem 0 .4rem; }
  .md-body h5, .md-body h6 { font-size: .88rem; font-weight: 600; margin: 1rem 0 .4rem; }
  .md-body h1:first-child { margin-top: 0; }

  .md-body p { margin: 0 0 .8rem; }

  .md-body ul, .md-body ol { margin: 0 0 .8rem; padding-left: 1.8rem; }
  .md-body li { margin-bottom: .25rem; }
  .md-body li > ul, .md-body li > ol { margin-top: .25rem; margin-bottom: 0; }

  /* Task lists */
  .md-body ul li { list-style: disc; }
  .md-body li input[type="checkbox"] {
    margin-right: .4rem; vertical-align: middle; position: relative; top: -1px;
  }

  .md-body a { color: var(--accent); text-decoration: none; }
  .md-body a:hover { text-decoration: underline; }

  .md-body strong { font-weight: 600; }

  .md-body blockquote {
    margin: 0 0 .8rem; padding: .4rem 1rem;
    border-left: 4px solid var(--accent); background: #f0f4f8;
    color: #555; font-size: .88rem;
  }
  .md-body blockquote p:last-child { margin-bottom: 0; }

  .md-body code {
    font-family: "SFMono-Regular", Consolas, "Liberation Mono", Menlo, monospace;
    font-size: .85em; background: #eef1f5; padding: .15rem .35rem;
    border-radius: 4px;
  }
  .md-body pre {
    margin: 0 0 .8rem; padding: .9rem 1rem;
    background: #f6f8fa; border: 1px solid var(--border);
    border-radius: 6px; overflow-x: auto; line-height: 1.45;
  }
  .md-body pre code {
    background: none; padding: 0; font-size: .82rem;
  }

  .md-body table {
    width: 100%; border-collapse: collapse; margin: 0 0 .8rem;
    font-size: .85rem; display: block; overflow-x: auto;
  }
  .md-body th, .md-body td {
    padding: .45rem .7rem; border: 1px solid var(--border); text-align: left;
  }
  .md-body th { background: #f0f4f8; font-weight: 600; }
  .md-body tr:nth-child(even) td { background: #fafbfc; }

  .md-body hr {
    border: none; border-top: 1px solid var(--border); margin: 1.5rem 0;
  }

  .md-body img { max-width: 100%; }

  /* Collapsible sections */
  .doc-controls { margin-bottom: 1rem; }
  .doc-controls button {
    font-size: .8rem; padding: .3rem .7rem; cursor: pointer;
    background: var(--card); border: 1px solid var(--border); border-radius: 4px;
    color: var(--accent); font-weight: 600;
  }
  .doc-controls button:hover { background: #e7f1ff; }
  .md-body details { margin-bottom: .5rem; }
  .md-body details summary {
    font-weight: 600; cursor: pointer; list-style: none;
  }
  .md-body details summary::-webkit-details-marker { display: none; }
  .md-body details summary::before {
    content: "\25b6"; font-size: .7em; margin-right: .5rem;
    display: inline-block; transition: transform .15s;
  }
  .md-body details[open] summary::before { transform: rotate(90deg); }
  .md-body details.level-2 > summary {
    font-size: 1.25rem; padding-bottom: .25rem;
    border-bottom: 1px solid var(--border); margin: 1.6rem 0 .6rem;
  }
  .md-body details.level-3 > summary {
    font-size: 1.05rem; margin: 1.3rem 0 .5rem;
  }

  footer {
    text-align: center; padding: 1.5rem; font-size: .8rem; color: var(--muted);
    border-top: 1px solid var(--border); margin-top: 2rem;
  }
</style>
</head>
<body>

<style>
  .site-nav {
    position: sticky; top: 0; z-index: 100;
    background: #212529; display: flex; align-items: center;
    padding: 0 2rem; height: 3rem;
  }
  .site-nav .nav-brand {
    color: #fff; text-decoration: none; font-weight: 600; font-size: 1rem;
    margin-right: auto;
  }
  .site-nav .nav-brand:hover { color: #e9ecef; }
  .site-nav .nav-link {
    color: #adb5bd; text-decoration: none; font-size: .85rem;
    padding: 0 .75rem; height: 3rem; display: flex; align-items: center;
    background: none; border: none; cursor: pointer; font-family: inherit;
  }
  .site-nav .nav-link:hover, .site-nav .nav-link.active { color: #fff; }
  .nav-dropdown { position: relative; }
  .dropdown-menu {
    display: none; position: absolute; top: 3rem; right: 0;
    background: #fff; border: 1px solid var(--border); border-radius: 6px;
    box-shadow: 0 4px 16px rgba(0,0,0,.12); min-width: 220px;
    padding: .4rem 0; z-index: 200; max-height: 80vh; overflow-y: auto;
  }
  .nav-dropdown.open .dropdown-menu { display: block; }
  .dropdown-menu a {
    display: block; padding: .3rem 1rem; color: #1a1a1a;
    text-decoration: none; font-size: .82rem;
  }
  .dropdown-menu a:hover { background: #f0f4f8; }
  .dropdown-group-label {
    padding: .4rem 1rem .15rem; font-size: .68rem; font-weight: 700;
    color: #888; text-transform: uppercase; letter-spacing: .04em;
  }
  .dropdown-divider { border-top: 1px solid #eee; margin: .3rem 0; }
  .page-header {
    padding: .8rem 2rem; border-bottom: 1px solid var(--border); background: #fff;
  }
  .page-header h1 { font-size: 1.3rem; font-weight: 600; }
  .page-header p { color: var(--muted); font-size: .85rem; margin-top: .15rem; }
</style>

<nav class="site-nav">
  <a href="../index.html" class="nav-brand">Judicialização da Saúde</a>
  <a href="../paper/index.html" class="nav-link">Paper</a>
  <div class="nav-dropdown">
    <button class="nav-link active">Docs &#9662;</button>
    <div class="dropdown-menu">
    <div class="dropdown-group-label">Research reference</div>
    <a href="../docs/README.html">Project Overview</a>
    <a href="../docs/summary.html">Research Summary</a>
    <a href="../docs/institutions.html">Institutional Background</a>
    <a href="../docs/data.html">Data Sources</a>
    <a href="../docs/methods.html">Empirical Methods</a>
    <a href="../docs/literature.html">Literature</a>
    <a href="../docs/theory.html">Theoretical Framework</a>
    <a href="../docs/hypotheses.html">Hypotheses & Evidence</a>
    <div class="dropdown-divider"></div>
    <div class="dropdown-group-label">Working notes</div>
    <a href="../docs/thinking.html">Open Questions & Ideas</a>
    <a href="../docs/decisions.html">Key Decisions</a>
    <a href="../docs/qa.html">Research Q&A</a>
    <div class="dropdown-divider"></div>
    <div class="dropdown-group-label">Task tracking</div>
    <a href="../docs/todo.html">Active Tasks</a>
    <a href="../docs/done.html">Completed Tasks</a>
    <div class="dropdown-divider"></div>
    <div class="dropdown-group-label">Communication</div>
    <a href="../docs/meetings.html">Meeting Notes</a>
    <a href="../docs/feedback.html">External Feedback</a>
    <div class="dropdown-divider"></div>
    <div class="dropdown-group-label">Court analysis</div>
    <a href="../docs/01-stf-reasoning-templates.html">STF Reasoning Templates</a>
    <a href="../docs/02-stj-repetitivos-patterns.html">STJ Repetitivos Patterns</a>
    <a href="../docs/03-tjsp-plans-vs-sus.html">TJSP: Plans vs SUS</a>
    <a href="../docs/04-conitec-pcdt-vs-courts.html">CONITEC vs Courts</a>
    <a href="../docs/05-interfederative-responsibility.html">Interfederative Responsibility</a>
    </div>
  </div>
  <div class="nav-dropdown">
    <button class="nav-link">Data &#9662;</button>
    <div class="dropdown-menu">
    <a href="../sources/tjsp.html">TJSP</a>
    <a href="../sources/datajud.html">DataJud</a>
    <a href="../sources/stf-stj.html">STF & STJ</a>
    <a href="../sources/trf3.html">TRF3</a>
    <a href="../sources/spending.html">Municipal Spending</a>
    <a href="../sources/legislation.html">Health Legislation</a>
    </div>
  </div>
  <a href="../references/index.html" class="nav-link">References</a>
  <a href="../news/index.html" class="nav-link">News</a>
</nav>
<script>
document.querySelectorAll('.nav-dropdown > .nav-link').forEach(function(btn) {
  btn.addEventListener('click', function(e) {
    e.stopPropagation();
    var dd = btn.parentElement;
    var wasOpen = dd.classList.contains('open');
    document.querySelectorAll('.nav-dropdown.open').forEach(function(d) { d.classList.remove('open'); });
    if (!wasOpen) dd.classList.add('open');
  });
});
document.addEventListener('click', function() {
  document.querySelectorAll('.nav-dropdown.open').forEach(function(d) { d.classList.remove('open'); });
});
</script>

<div class="page-header">
  <h1>Institutional Background</h1>
</div>

<main>
<div class="doc-controls">
  <button id="toggle-sections">Expand all</button>
</div>
<div class="md-body">
<h1>Institutional Setting — Source of Truth</h1>
<p>This document is the <strong>single reference</strong> for institutional facts used in the
paper. Before writing any institutional claim in <code>paper/main.tex</code>, check here
first. Before adding new facts, search this document to avoid duplication.</p>
<p>Every factual claim must have an inline source attribution. Items marked
<strong>NEEDS PRIMARY SOURCE</strong> require verification before use in the paper.</p>
<p>Last updated: 2026-02-09</p>
<hr />
<h2 id="table-of-contents">Table of Contents</h2>
<table>
<thead>
<tr>
  <th>#</th>
  <th>Section</th>
  <th>What it covers</th>
  <th>Key for</th>
</tr>
</thead>
<tbody>
<tr>
  <td>1</td>
  <td><a href="#1-the-brazilian-public-health-system-sus">SUS</a></td>
  <td>Constitutional framework, SUS organization, coverage, service delivery gaps, fiscal decentralization, pharma components (CBAF/CESAF/CEAF), RENAME/CONITEC, spending floors</td>
  <td>Background (§3.1)</td>
</tr>
<tr>
  <td>2</td>
  <td><a href="#2-court-system-structure">Court structure</a></td>
  <td>TJSP, TRF3, jurisdiction rules by drug type/cost</td>
  <td>Background (§3.2), Data (§4.1)</td>
</tr>
<tr>
  <td>3</td>
  <td><a href="#3-case-assignment-distribui%C3%A7%C3%A3o">Case assignment</a></td>
  <td>Random assignment mechanism, exceptions (prevenção, conexão), implications for Judge IV</td>
  <td>Identification (§5)</td>
</tr>
<tr>
  <td>4</td>
  <td><a href="#4-health-litigation-process">Litigation process</a></td>
  <td>Case composition, filing, injunctions, grant rates, judicial discretion margins, enforcement, appeals, procurement</td>
  <td>Background (§3.3–3.6), Identification</td>
</tr>
<tr>
  <td>5</td>
  <td><a href="#5-defendant-identity-and-fiscal-incidence">Defendant &amp; fiscal incidence</a></td>
  <td>Solidary liability, who pays, reimbursement, cost premium, budget impact</td>
  <td>Background (§3.4, 3.6)</td>
</tr>
<tr>
  <td>6</td>
  <td><a href="#6-volume-and-geographic-distribution">Volume &amp; distribution</a></td>
  <td>Federal spending growth, spending concentration, caseload, geographic split (capital vs. interior), growth trends</td>
  <td>Data (§4.1), Sample</td>
</tr>
<tr>
  <td>7</td>
  <td><a href="#7-key-jurisprudential-milestones">Jurisprudential milestones</a></td>
  <td>Tema 106, 500, 793, 1.234; SV 60/61; impact evidence</td>
  <td>Background (§3.5)</td>
</tr>
<tr>
  <td>8</td>
  <td><a href="#8-venue-choice-and-forum-shopping">Venue choice</a></td>
  <td>No judge-shopping, entity-dimension forum shopping, comarca mapping</td>
  <td>Identification (§5)</td>
</tr>
<tr>
  <td>9</td>
  <td><a href="#9-key-data-sources-for-the-paper">Data sources</a></td>
  <td>TCE-SP, SIOPS, DATASUS, S-CODES, subfunção structure</td>
  <td>Data (§4)</td>
</tr>
<tr>
  <td>10</td>
  <td><a href="#10-key-empirical-facts-for-calibration-and-motivation">Key empirical facts</a></td>
  <td>Summary table of numbers used in the paper</td>
  <td>All sections</td>
</tr>
</tbody>
</table>
<hr />
<h2 id="1-the-brazilian-public-health-system-sus">1. The Brazilian Public Health System (SUS)</h2>
<p>&lt;!-- Updated: 2026-02-09 | Sources: CF/88, Lei 8.080/1990, Portaria GM/MS 1.555/2013, LC 141/2012, castro2019lancet, macinko2006jech, cnm2022, cgu2021conitec, cfm2024, folha2025incorporation --&gt;</p>
<h3 id="constitutional-framework">Constitutional framework</h3>
<ul>
<li>Health is a right of all and a duty of the State. [CF/88 Art. 196]</li>
<li>Health services form a regionalized, hierarchical network constituting the
Unified Health System (SUS). Three directives: decentralization, comprehensive
care (<em>integralidade</em>), community participation. [CF/88 Art. 198]</li>
<li>All three levels of government (Union, States, Municipalities) share
responsibility for health (<em>competência comum</em>). [CF/88 Art. 23(II)]</li>
</ul>
<h3 id="organization">Organization</h3>
<p>SUS is organized by the Lei Orgânica da Saúde. Municipalities are the primary
executors of health policy (decentralization principle). [Lei 8.080/1990,
Arts. 6–7] The Comissão Intergestores Tripartite (CIT) coordinates between
federal, state, and municipal health managers. [Lei 8.080/1990 Art. 14-A;
CIT Resolução Consolidada 2021]</p>
<h3 id="pharmaceutical-assistance-components">Pharmaceutical assistance components</h3>
<p>Medications within SUS are organized into three financing components, each
defining which level of government is responsible for procurement and cost:</p>
<table>
<thead>
<tr>
  <th>Component</th>
  <th>Responsibility</th>
  <th>Coverage</th>
  <th>Source</th>
</tr>
</thead>
<tbody>
<tr>
  <td><strong>CBAF</strong> (Componente Básico)</td>
  <td>Municipality finances and acquires</td>
  <td>Basic drugs for primary care (diabetes, hypertension)</td>
  <td>[Portaria GM/MS 1.555/2013]</td>
</tr>
<tr>
  <td><strong>CESAF</strong> (Componente Estratégico)</td>
  <td>Union acquires; States distribute</td>
  <td>Drugs for endemic/strategic diseases (HIV, TB, malaria)</td>
  <td>[Portaria GM/MS 1.555/2013]</td>
</tr>
<tr>
  <td><strong>CEAF</strong> (Componente Especializado)</td>
  <td>Shared by tiers (see below)</td>
  <td>High-cost drugs for chronic/rare diseases</td>
  <td>[Portaria GM/MS 1.555/2013]</td>
</tr>
</tbody>
</table>
<p>CEAF is further divided [Portaria GM/MS 1.555/2013]:</p>
<ul>
<li><strong>Group 1A:</strong> Union finances and acquires.</li>
<li><strong>Group 1B:</strong> Union finances; States acquire.</li>
<li><strong>Group 2:</strong> States finance and acquire.</li>
<li><strong>Group 3:</strong> Municipal responsibility.</li>
</ul>
<h3 id="rename-and-conitec">RENAME and CONITEC</h3>
<ul>
<li><strong>RENAME</strong> (Relação Nacional de Medicamentos Essenciais): the national list of
drugs that SUS is obligated to provide. Updated periodically. [Lei 8.080/1990
Art. 19-M, as amended by Lei 12.401/2011]</li>
<li><strong>CONITEC</strong> (Comissão Nacional de Incorporação de Tecnologias no SUS): evaluates
drugs for incorporation into SUS based on efficacy, safety, and
cost-effectiveness. A drug not on RENAME is &quot;not incorporated&quot; and not
routinely provided by SUS. [Lei 12.401/2011]</li>
</ul>
<h3 id="population-coverage">Population coverage</h3>
<ul>
<li>Approximately 75% of the population (~160 million people) relies exclusively
on SUS for health care. The remaining ~25% hold supplementary private
insurance, concentrated among higher-income households, but retain the right
to use SUS services. [castro2019lancet]</li>
</ul>
<h3 id="service-delivery-tiers">Service delivery tiers</h3>
<ul>
<li><strong>Primary care:</strong> Family Health Strategy (ESF) covers over 60% of the
population. [macinko2006jech] <strong>NEEDS PRIMARY SOURCE — 2006 figure may be
outdated; current ESF coverage likely higher</strong></li>
<li><strong>Secondary/tertiary care:</strong> Public hospitals, contracted private providers,
and university hospitals organized into regional referral networks.</li>
</ul>
<h3 id="fiscal-decentralization">Fiscal decentralization</h3>
<ul>
<li>Municipal share of total public health spending rose from 29% (2012) to 34%
(2022); federal share declined from 45% to 38%. <strong>NEEDS PRIMARY SOURCE</strong> —
cited without attribution in the paper; likely SIOPS or CONASEMS data.</li>
<li>Municipalities bear increasing financial responsibility for health while also
being the most exposed to court-mandated spending.</li>
</ul>
<h3 id="service-delivery-gaps">Service delivery gaps</h3>
<ul>
<li>Over 80% of municipalities reported shortages of basic medicines in their
public pharmacies (2022 national survey). [cnm2022]</li>
<li>Federal audit: none of 25 sampled medications met the statutory 180-day
availability deadline after CONITEC incorporation. [cgu2021conitec]</li>
<li>Estimated 900,000 patients awaiting elective procedures nationally. [cfm2024]</li>
<li>Nearly one-third of medicines incorporated since 2018 remained unavailable to
patients, with an average delay of 648 days from incorporation to delivery
(as of early 2025). [folha2025incorporation]</li>
</ul>
<h3 id="health-spending-floors">Health spending floors</h3>
<p>The Constitution mandates minimum health spending [EC 29/2000; LC 141/2012]:</p>
<ul>
<li>Municipalities: 15% of own-source revenue.</li>
<li>States: 12% of own-source revenue.</li>
<li>Union: formula-based floor linked to prior-year spending + GDP growth.</li>
</ul>
<p>Failure to meet floors or to report to SIOPS can result in suspension of
federal/state transfers. [LC 141/2012 Art. 26]</p>
<hr />
<h2 id="2-court-system-structure">2. Court System Structure</h2>
<p>&lt;!-- Updated: 2026-02-06 | Sources: TJSP data, CNJ Res. 238/2016, CF/88 | 2 items unverified (vara counts) --&gt;</p>
<h3 id="tjsp-tribunal-de-justi-a-de-s-o-paulo">TJSP (Tribunal de Justiça de São Paulo)</h3>
<p>TJSP is the state court for São Paulo — the largest court system in Latin
America by caseload. [CNJ, Justiça em Números]</p>
<p><strong>Structure:</strong></p>
<ul>
<li><strong>322 comarcas</strong> handle health litigation. [TJSP full collapsed sentença data]</li>
<li><strong>3,006 unique judges</strong> active in health cases across these comarcas. [TJSP full collapsed sentença data]</li>
<li>São Paulo Capital has multiple Varas da Fazenda Pública (exact count not
confirmed in available sources — verify via TJSP website).</li>
<li>Interior comarcas typically have 1–3 varas da fazenda pública each (verify
via TJSP organizational data).</li>
</ul>
<p><strong>Varas da Fazenda Pública</strong> are the specialized courts that hear cases against
the government (municipal and state). Health cases against public entities are
filed here. [CPC Art. 64; NSCGJ/TJSP]</p>
<p><strong>Health specialization:</strong> In comarcas with more than one Vara da Fazenda
Pública, the court must specialize one vara for public health matters, with
compensating redistribution of other case types. [CNJ Resolution 238/2016 Art. 3]</p>
<p><strong>CADIP</strong> (Centro de Apoio ao Direito Público) provides guidance to judges via
the &quot;Caderno de Judicialização da Saúde.&quot; [TJSP/CADIP]</p>
<h3 id="trf3-tribunal-regional-federal-da-3-regi-o">TRF3 (Tribunal Regional Federal da 3ª Região)</h3>
<p>TRF3 is the federal court covering São Paulo and Mato Grosso do Sul. [CF/88 Art. 106]</p>
<ul>
<li>Handles cases against the <strong>Union</strong> and <strong>INSS</strong>. [CF/88 Art. 109]</li>
<li>Also has automated random case assignment. [CPC Art. 284–285; CNJ administrative rules]</li>
<li>CNJ Resolution 238/2016 also applies (health specialization). [CNJ Res. 238/2016]</li>
<li>Much smaller volume than TJSP for health cases. Handles cases against the
Union, which include high-cost drugs under CEAF Group 1A. [CF/88 Art. 109;
Portaria GM/MS 1.555/2013]</li>
</ul>
<h3 id="jurisdiction-rules">Jurisdiction rules</h3>
<table>
<thead>
<tr>
  <th>Scenario</th>
  <th>Court</th>
  <th>Defendant</th>
  <th>Source</th>
</tr>
</thead>
<tbody>
<tr>
  <td>Drug on RENAME (CBAF)</td>
  <td>TJSP</td>
  <td>Municipality</td>
  <td>[SUS administrative rules]</td>
</tr>
<tr>
  <td>Drug on RENAME (CEAF Groups 1–2)</td>
  <td>TJSP or TRF3</td>
  <td>State or Union</td>
  <td>[SUS administrative rules]</td>
</tr>
<tr>
  <td>Drug not on RENAME, cost &lt;210 min. salaries</td>
  <td>TJSP</td>
  <td>State or Municipality</td>
  <td>[STF Tema 1.234 (2024)]</td>
</tr>
<tr>
  <td>Drug not on RENAME, cost ≥210 min. salaries</td>
  <td>TRF3</td>
  <td>Union</td>
  <td>[STF Tema 1.234 (2024)]</td>
</tr>
<tr>
  <td>Drug without ANVISA registration</td>
  <td>TRF3</td>
  <td>Union</td>
  <td>[STF Tema 500 (2019)]</td>
</tr>
</tbody>
</table>
<hr />
<h2 id="3-case-assignment-distribui-o">3. Case Assignment (Distribuição)</h2>
<p>&lt;!-- Updated: 2026-02-06 | Sources: CPC, NSCGJ, CNJ Res. 238/2016 | Fully sourced --&gt;</p>
<h3 id="random-assignment-mechanism">Random assignment mechanism</h3>
<p>Case assignment at both TJSP and TRF3 is conducted through an <strong>automated,
sequential distribution system</strong> that is effectively random. The system ensures
balanced workloads and prevents litigants from selecting a specific judge.
[CPC Art. 284–285; NSCGJ/TJSP]</p>
<h3 id="exceptions-to-random-assignment">Exceptions to random assignment</h3>
<ul>
<li><strong>Prevenção (prevention):</strong> If a related case exists (same <em>causa de pedir</em> or
same object), the new case is routed to the judge who first presided.
[CPC Art. 59]</li>
<li><strong>Conexão and continência:</strong> Connected or contained cases may be joined before
the same judge for judicial economy. [CPC Arts. 55–57]</li>
<li><strong>Health specialization (CNJ 238/2016):</strong> In comarcas with multiple varas da
fazenda pública, health cases go to the specialized vara. This is random
<em>conditional on</em> filing in a health-specialized vara. [CNJ Res. 238/2016]</li>
</ul>
<h3 id="implications-for-judge-iv-design">Implications for Judge IV design</h3>
<ul>
<li><strong>Random assignment within a vara/comarca is confirmed.</strong> Supports the core
identification assumption. [CPC; NSCGJ]</li>
<li><strong>Prevenção is the main threat:</strong> related cases routed to the same judge create
non-random clustering. Need to identify and handle these. [CPC Art. 59]</li>
<li><strong>Specialization reduces the judge pool</strong> in some comarcas but makes assignment
cleaner. [CNJ Res. 238/2016]</li>
<li><strong>No judge-shopping by litigants</strong> — automated system prevents this.
[CPC Art. 284–285; NSCGJ/TJSP]</li>
</ul>
<hr />
<h2 id="4-health-litigation-process">4. Health Litigation Process</h2>
<p>&lt;!-- Updated: 2026-02-09 | Sources: CNJ/Insper 2019, TJSP data, Ipea 2025, STJ Temas 84/98, TCU, tcu2017, biehl2009lancet, chieffi2009csp, ipea_anadep2013, biehl2015csp --&gt;</p>
<h3 id="filing">Filing</h3>
<ul>
<li>Plaintiff (patient) files in their <strong>home comarca</strong> (domicile). [CPC Art. 46]</li>
<li>For suits against municipalities: filed in the comarca where the municipality
is located (usually the same as plaintiff's domicile). [CPC Art. 46;
TJSP Súmula 37]</li>
<li>For suits against the State: plaintiff can choose the state capital or their
own domicile. [CPC Art. 52]</li>
<li><strong>Private attorneys</strong> represent the vast majority of litigants, especially in
health plan cases (~55% of TJSP annual health volume). [Sintese Tjsp Planos
Vs Sus, p. 811; CNJ/Insper 2019, p. 107]</li>
<li><strong>Defensoria Pública</strong> handles approximately <strong>6.91%</strong> of first-instance
sentencing volume at TJSP. Eligibility: family income up to 3 minimum
salaries. Coverage is concentrated in urban hubs; interior comarcas have
significant gaps. [TJSP Sentencas Summary, p. 1364; CNJ/Insper 2019, p. 107]</li>
<li><strong>Defensoria coverage gap:</strong> public defenders were absent from <strong>72%</strong> of
Brazilian comarcas as of 2013. [ipea_anadep2013]</li>
<li><strong>Defensoria litigation effect:</strong> Defensoria presence is associated with a
<strong>seven-fold</strong> increase in the probability of health litigation.
[biehl2015csp]</li>
<li><strong>Ministério Público</strong> handles <strong>3.11%</strong> of first-instance cases, primarily
collective actions (Ações Civis Públicas). [TJSP Sentencas Summary, p. 1364]</li>
<li>Only ~<strong>20%</strong> of health litigants are identified as economically vulnerable.
[CNJ 2021, p. 269]</li>
<li><strong>Litigation concentration:</strong> 6 lawyers were responsible for 35% of all
health cases against the state in a single year; a single physician wrote
66% of prescriptions for a specific judicialized drug. [TCU Orcamento
Judicializacao, p. 980]</li>
</ul>
<h3 id="case-composition">Case composition</h3>
<ul>
<li><strong>Medicines dominate:</strong> approximately 80% of health cases. [tcu2017]</li>
<li><strong>On-formulary share:</strong> over 50% of medication lawsuits in some jurisdictions
request drugs already on SUS formularies, suggesting litigation often
addresses administrative delivery failures rather than genuine coverage gaps.
[biehl2009lancet; chieffi2009csp]</li>
<li>Beyond medicines: lawsuits seek surgical procedures, hospital beds, and
medical devices.</li>
</ul>
<h3 id="preliminary-injunctions-tutela-antecipada">Preliminary injunctions (tutela antecipada)</h3>
<ul>
<li>Judges frequently grant preliminary injunctions in health cases, with a median
of <strong>10 days</strong> to grant at TJSP. [Tutela Provisoria Senado, p. 1443–1444]</li>
<li>There is a documented &quot;automatism&quot; in granting: judges often defer to the
medical prescription without consulting health managers or technical bodies.
[CNJ/Insper 2019, p. 84]</li>
<li>Since 2016, judges are encouraged to consult <strong>NAT-Jus</strong> via the <strong>e-NatJus</strong>
system for technical opinions. However, fewer than <strong>6%</strong> of decisions cite
technical standards like CONITEC or RENAME (national first-instance average).
[CNJ/Insper 2019, p. 91]</li>
<li><strong>TJSP specifically:</strong> fewer than <strong>0.01%</strong> of first-instance health decisions
cited NAT-Jus — 9 of 107,497 cases. [CNJ/Insper 2019, p. 91]</li>
<li>Geographic variation is substantial: e.g., <strong>Mato Grosso</strong> courts cited
technical notes in <strong>18%</strong> of cases. [CNJ/Insper 2019]</li>
<li>Average time from filing to full sentence at TJSP: approximately <strong>one year
and nine months</strong>. [Tutela Provisoria Senado, p. 1444]</li>
<li>National average from filing to final judgment (<em>trânsito em julgado</em>):
<strong>432 days</strong>. [Stf Temas Desafios Academico, p. 889]</li>
</ul>
<h3 id="grant-rates">Grant rates</h3>
<table>
<thead>
<tr>
  <th>Scope</th>
  <th>Grant rate</th>
  <th>Source</th>
</tr>
</thead>
<tbody>
<tr>
  <td>All health cases (TJSP, incl. disability/plans)</td>
  <td>~67%</td>
  <td>[TJSP sentença data]</td>
</tr>
<tr>
  <td>SUS cases against municipalities (full + partial)</td>
  <td>~87%</td>
  <td>[TJSP sentença data]</td>
</tr>
<tr>
  <td>Medication/treatment cases against municipalities</td>
  <td>~93%</td>
  <td>[TJSP sentença data]</td>
</tr>
<tr>
  <td>Preliminary injunctions (SP city)</td>
  <td>~85%</td>
  <td>[Wang &amp; Ferraz 2013]</td>
</tr>
<tr>
  <td>Brazilian health litigation (general)</td>
  <td>&gt;90%</td>
  <td>[Biehl et al. 2012]</td>
</tr>
</tbody>
</table>
<p>Approximately <strong>10.4%</strong> of TJSP sentences are partially granted (limiting
duration, requiring periodic reports, allowing generic substitution).
[TJSP sentença data]</p>
<h3 id="margins-of-judicial-discretion">Margins of judicial discretion</h3>
<p>Even with high grant rates, judges vary on several margins [CNJ/Insper 2019;
TJSP Sentencas Summary]:</p>
<ol>
<li><strong>Speed:</strong> Immediate injunction (days) vs. waiting for full trial (months/years).</li>
<li><strong>Scope:</strong> Exact brand-name drug vs. generic substitute vs. SUS alternative.
Enunciado 28 (CNJ Health Journeys) directs judges to require technical
descriptions rather than brand names. [Enunciado 28]</li>
<li><strong>Enforcement intensity:</strong> Direct fund seizure (<em>bloqueio/sequestro</em>) from
municipal bank accounts vs. softer compliance mechanisms.</li>
<li><strong>Partial vs. full grant:</strong> Limiting duration, requiring periodic medical
reports (Enunciado 2), or capping quantities.</li>
<li><strong>NAT-Jus consultation:</strong> Whether the judge seeks and follows technical advice.</li>
<li><strong>Financial incapacity verification:</strong> Under Tema 6 (STF), judges must verify
plaintiff cannot afford the treatment (for non-incorporated drugs).</li>
</ol>
<h3 id="enforcement-and-compliance">Enforcement and compliance</h3>
<p>When a government entity fails to comply with a court order, three enforcement
tools are available:</p>
<ol>
<li><strong>Bloqueio/sequestro de verbas (fund seizure):</strong> Direct seizure of funds from
the municipal bank account. Most common and effective tool. Legality
established under <strong>STJ Tema 84</strong>. [Tjsp Caderno Judicializacao 2024, p. 1038]</li>
<li><strong>Multa diária (astreintes):</strong> Daily fines on the public entity to compel
compliance. Validated by <strong>STJ Tema 98</strong>. [Tjsp Caderno Judicializacao 2024, p. 1038]</li>
<li><strong>Responsabilização pessoal:</strong> Public officials (including health secretaries)
can face personal liability for non-compliance, including charges for crime
of disobedience under <strong>Penal Code Art. 330</strong>. [Mandado Seguranca Lei 12016, p. 630]</li>
</ol>
<p>Fund seizures are described by managers as &quot;catastrophic&quot; for fiscal planning,
as they extract liquidity regardless of existing municipal commitments.
[CNJ/Insper 2019, p. 202]</p>
<p>Only <strong>50–60% of municipal health secretariats</strong> have dedicated legal or
management units to handle judicial demands. [CNJ 2021, p. 270]</p>
<h3 id="appeals">Appeals</h3>
<ul>
<li>Approximately <strong>55%</strong> of first-instance health cases are appealed to the
second instance (national data, 2008–2017: 277,411 of 498,715 cases).
[CNJ/Insper 2019, p. 87]</li>
<li>States and municipalities are the primary appellants, often appealing as an
administrative duty regardless of success probability. [CNJ/Insper 2019, p. 88]</li>
<li><strong>Reversals are rare in practice</strong> because most orders are already enforced
via preliminary injunction, and many cases are rendered moot by compliance.
[CNJ/Insper 2019, p. 84]</li>
<li>Treatments are treated as <strong>&quot;irrepetíveis&quot; (non-returnable)</strong> once consumed,
especially for financially incapacitated patients. The fiscal impact occurs
at the preliminary stage and persists regardless of appellate outcome.
[Tutela Provisoria Mpsp, p. 1411–1412; Stf Tema 6, p. 885]</li>
<li>The <strong>Câmaras de Direito Público</strong> at TJSP handle SUS appeals and apply
binding precedents (e.g., Tema 793). They increasingly consult NAT-Jus
before confirming/reversing lower court decisions. [Sintese Tjsp Planos Vs
Sus, p. 820; CNJ/Insper 2019, p. 91; Sumulas Vinculantes 60 61 Saude, p. 916]</li>
</ul>
<h3 id="procurement-of-judicially-mandated-medicines">Procurement of judicially mandated medicines</h3>
<p>Municipalities rely on <strong>emergency purchases (dispensa de licitação)</strong> because
court orders mandate compliance within 24 hours to 15 days. Standard bidding
under Law 8.666/1993 is too slow. [Ipea 2025, p. 557; Conass Financiamento
Sus 2023, p. 383; CNJ/Insper 2019, p. 334]</p>
<p>Judges sometimes grant direct access to municipal accounts, allowing the
plaintiff to purchase at a commercial pharmacy at market prices. [CNJ/Insper
2019, p. 200]</p>
<p><strong>Price benchmarks:</strong> STF Tema 1.234 (2024) set a ceiling at the PMVG at
zero-percent tax or the CONITEC incorporation discount, whichever is lower.
[Stf Temas 6 1234 Manual Pge, p. 878] However, pre-2024 no effective price
constraint existed.</p>
<p><strong>The 30–44% cost premium</strong> (vs. standard SUS procurement) is explained by:</p>
<ul>
<li>Retail buying: single-unit purchases at higher unit costs. [CNJ/Insper 2019,
p. 196; Ipea 2025, p. 577]</li>
<li>Brand specificity: courts mandate specific brands rather than generics.
[Enunciados Jornadas Saude Consolidado, p. 405; Ipea 2025, p. 577]</li>
<li>Strategic industry behavior: pharmaceutical companies delay ANVISA
registration or CONITEC incorporation to profit from higher non-negotiated
prices in the judicial channel. [Ipea 2025, p. 577]</li>
</ul>
<p><strong>Administrative paths:</strong> 52.1% of municipalities have created extrajudicial
provision mechanisms to prevent lawsuits. [Ipea 2025, p. 545, 578]
Some regions use <strong>inter-municipal consortiums</strong> for pooled procurement.
[CNJ/Insper 2019, p. 303]</p>
<hr />
<h2 id="5-defendant-identity-and-fiscal-incidence">5. Defendant Identity and Fiscal Incidence</h2>
<p>&lt;!-- Updated: 2026-02-09 | Sources: CF/88, STF Temas 793/1.234, Fiocruz 2020, Ipea 2025, wang2014rap, folha2025elevidys, theconversation2024, diniz2014csc --&gt;</p>
<h3 id="solidary-liability">Solidary liability</h3>
<p>Under the Constitution, all three levels of government are jointly and severally
liable (<em>responsabilidade solidária</em>) for health. [CF/88 Arts. 23(II), 196, 198]</p>
<p><strong>Tema 793 (STF, 2019)</strong> refined this: while liability remains solidary, judges
must <strong>direct compliance to the administratively responsible entity</strong> and order
reimbursement between entities. Judges should include the responsible entity
<em>ex officio</em> if not already named. [STF Tema 793]</p>
<h3 id="who-actually-pays">Who actually pays</h3>
<p><strong>Municipalities bear the immediate fiscal burden in most cases</strong>
[Fiocruz 2020, p. 463; CNJ/Insper 2019, p. 200]:</p>
<ul>
<li>They are the easiest to sue (local court, local judges).</li>
<li>Smaller municipalities are frequently sued for treatments that are
administratively the state's or federal government's responsibility.
[Fiocruz 2020, p. 463]</li>
<li>Fund seizure (<em>bloqueio</em>) from municipal bank accounts is common.
[Tjsp Caderno Judicializacao 2024, p. 1038; STJ Tema 84]</li>
</ul>
<p><strong>Reimbursement mechanisms (mostly post-2024):</strong></p>
<ul>
<li>Under Tema 1.234, for non-incorporated drugs costing 7–210 minimum salaries,
the Union must reimburse <strong>65%</strong> when a State or Municipality is condemned.
[STF Tema 1.234 (2024)]</li>
<li>For oncology treatments filed before June 2024, the Union reimburses <strong>80%</strong>.
[STF Tema 1.234 (2024)]</li>
<li>Courts must cap reimbursement at the <strong>PMVG</strong> (maximum government price).
[STF Tema 1.234 (2024)]</li>
<li><strong>Pre-2024, no systematic reimbursement existed</strong> — municipalities bore the
full cost. [Institutional fact; confirmed by absence of reimbursement
mechanism prior to STF Temas 1.234/6 (2024)]</li>
</ul>
<h3 id="cost-premium">Cost premium</h3>
<p>Judicial drug purchases are <strong>30–44% more expensive</strong> than regular SUS
procurement because they bypass competitive bidding processes.
[Genicolo-Martins &amp; Furquim de Azevedo 2024]</p>
<h3 id="fiscal-mismatch">Fiscal mismatch</h3>
<ul>
<li>In the municipality of São Paulo, <strong>55%</strong> of court-mandated pharmaceutical
spending corresponded to medicines that were the responsibility of the state
or federal government. [wang2014rap]</li>
</ul>
<h3 id="budget-impact">Budget impact</h3>
<ul>
<li><strong>Total MoH judicial compliance costs:</strong> R$2.7 billion (2024), including
pharmaceutical assistance (R$1.9B) and other compliance costs. Equivalent to
the entire budget of Farmácia Popular. [folha2025elevidys]</li>
<li>Over <strong>270 municipalities</strong> devoted between 30 and 100 percent of their health
budgets to fulfilling judicial mandates in 2024. [theconversation2024]</li>
<li>Judicialized medications consume <strong>8.4% of municipal pharmaceutical budgets</strong>
on average (2023). [Ipea Gastos Judicializacao 2025, p. 545]</li>
<li>In 271 municipalities (2019–2023), total medication spending grew 30% while
judicially mandated medication spending grew 22%. [Ipea Gastos Judicializacao
2025, p. 560]</li>
<li>In Campinas, judicial health spending reached <strong>16%</strong> of the pharmaceutical
budget in 2009; over half of the budget in some smaller municipalities.
[diniz2014csc]</li>
<li>In a 2022 sample of 43 SP municipalities, 72% had tagged judicial health
expenditures, with shares ranging from 0.0% to 6.8% of total health budgets.
[Our TCE-SP data exploration, Feb 2025]</li>
<li><strong>Formal budget reallocation evidence:</strong> TCE-SP Alterações Orçamentárias data
(2015–2019) shows 34 of 644 municipalities creating explicit judicial budget
lines (e.g., Santos: &quot;MANDADOS JUDICIAIS / MED. E INSUMOS NAO PACTUADOS&quot;
under Suporte Profilático e Terapêutico, with zero initial dotação, receiving
supplementary credits funded by anulação de dotação from other health lines).
[Our TCE-SP Alterações Orçamentárias exploration, Feb 2026]</li>
<li>State-level judicialized medication spending reached <strong>32.9% of total state
pharmaceutical expenditures</strong> by 2023. [Ipea Gastos Judicializacao 2025,
p. 545, 568]</li>
</ul>
<hr />
<h2 id="6-volume-and-geographic-distribution">6. Volume and Geographic Distribution</h2>
<p>&lt;!-- Updated: 2026-02-09 | Sources: TJSP data, CNJ/Insper 2019, Ipea 2025, tcu2017, vieira2020hhr, cambricoli2016estadao --&gt;</p>
<h3 id="federal-spending-growth">Federal spending growth</h3>
<ul>
<li>Federal spending on judicial compliance for medicines rose <strong>thirteen-fold</strong>
in seven years: R$70 million (2008) → over R$1 billion (2015). [tcu2017]</li>
<li>By 2024, reached R$1.9 billion (pharmaceutical assistance alone). [ipea2025]</li>
</ul>
<h3 id="spending-concentration">Spending concentration</h3>
<ul>
<li>More than <strong>half of federal judicial health expenditures</strong> between 2010 and
2015 were concentrated in just <strong>three medicines</strong> not on the essential list.
[vieira2020hhr]</li>
<li>Non-registered drugs (without ANVISA registration) accounted for <strong>R$545
million</strong> of MoH judicial compliance spending by 2015, up from <strong>R$2.4
million</strong> in 2010. [cambricoli2016estadao]</li>
</ul>
<h3 id="caseload-at-tjsp">Caseload at TJSP</h3>
<ul>
<li><strong>~325,000 new health cases/year</strong> at TJSP: ~55% (~180,000) private health
plans, ~37% (~120,000) SUS cases. [Sintese Tjsp Planos Vs Sus, p. 811]</li>
<li>Over 2005–2024, TJSP processed <strong>1.29 million</strong> health sentenças across
<strong>3,006 judges</strong> and <strong>322 comarcas</strong>. [TJSP full collapsed sentença data]</li>
<li>Growth: SUS cases grew from 2,317 (2008) to 23,465 (2017).
[CNJ/Insper 2019, p. 87]</li>
<li>Post-2020, national 1st-instance public health case volume more than doubled:
76,836 (2020) → 162,046 (2024), a 110.9% increase. [Ipea Gastos
Judicializacao 2025, p. 547]</li>
</ul>
<h3 id="geographic-distribution">Geographic distribution</h3>
<ul>
<li><strong>São Paulo Capital:</strong> ~23.1% of health litigation. [TJSP sentença data]</li>
<li><strong>Interior:</strong> ~76.9% across 321 comarcas (= 322 total minus capital). [TJSP sentença data] <strong>NOTE:</strong> Previous version said 313; corrected to 321 for arithmetic consistency with the 322 total. If 313 referred to a specific subset (e.g., comarcas with &gt;N cases), this should be verified against the raw data.</li>
<li>Concentration in ABCD region (São Bernardo do Campo, Diadema, Santo André,
Mauá), Campinas, Guarulhos, São José dos Campos. [Tjsp Sentencas Summary,
p. 1363]</li>
<li>100% of municipalities &gt;500,000 inhabitants have active health litigation.
[Ipea Gastos Judicializacao 2025, p. 556]</li>
<li>Among municipalities &lt;5,000 inhabitants, <strong>36.5%</strong> report providing
medications due to court orders. [Ipea Gastos Judicializacao 2025, p. 555]</li>
</ul>
<h3 id="relevance-for-our-design">Relevance for our design</h3>
<ul>
<li>77% interior matches TCE-SP coverage (644 municipalities, excludes SP capital
under TCM-SP). [Our TCE-SP data exploration; TJSP sentença data]</li>
<li>Losing SP capital (~23% of caseload) is manageable for the municipal-level
analysis.</li>
<li>Rapid growth provides time variation; jurisprudential shocks provide natural
experiments.</li>
</ul>
<hr />
<h2 id="7-key-jurisprudential-milestones">7. Key Jurisprudential Milestones</h2>
<p>&lt;!-- Updated: 2026-02-09 | Sources: STF/STJ rulings, CNJ Res. 238, CNJ/Insper 2019, STF Pet 1246-SC, cnjpnud2025 --&gt;</p>
<h3 id="origin-of-individual-right-to-health">Origin of individual right to health</h3>
<ul>
<li><strong>Pet 1246-SC (STF, 1997):</strong> Landmark decision ordering a state to fund
treatment abroad for a child with a rare disease. Justice Celso de Mello held
that &quot;the individual right to life takes precedence over the financial and
secondary interest of the State.&quot; This reasoning — treating the constitutional
provision as an immediately enforceable individual entitlement to specific
treatments — was rapidly adopted by lower courts across the country.
[STF Pet 1246-SC; ferraz2009hhr; wang2015hepl]</li>
</ul>
<h3 id="key-rulings">Key rulings</h3>
<p>These rulings changed the rules of health litigation and create natural
variation in the data:</p>
<table>
<thead>
<tr>
  <th>Year</th>
  <th>Ruling</th>
  <th>What it changed</th>
  <th>Source</th>
</tr>
</thead>
<tbody>
<tr>
  <td>1997</td>
  <td><strong>Pet 1246-SC</strong> (STF)</td>
  <td>Established individual right to health as immediately justiciable, not merely programmatic</td>
  <td>[STF Pet 1246-SC]</td>
</tr>
<tr>
  <td>2016</td>
  <td>CNJ Resolution 238</td>
  <td>Created health-specialized varas and NAT-Jus system</td>
  <td>[CNJ Res. 238/2016]</td>
</tr>
<tr>
  <td>2018</td>
  <td><strong>Tema 106</strong> (STJ, REsp 1.657.156)</td>
  <td>Three cumulative requirements for non-RENAME drugs: (1) medical necessity + SUS ineffectiveness, (2) financial incapacity, (3) ANVISA registration. Applied from May 4, 2018.</td>
  <td>[STJ Tema 106]</td>
</tr>
<tr>
  <td>2019</td>
  <td><strong>Tema 500</strong> (STF)</td>
  <td>State generally cannot provide drugs without ANVISA registration</td>
  <td>[STF Tema 500]</td>
</tr>
<tr>
  <td>2019</td>
  <td><strong>Tema 793</strong> (STF)</td>
  <td>Solidary liability clarified: judges must direct compliance to administratively responsible entity</td>
  <td>[STF Tema 793]</td>
</tr>
<tr>
  <td>2024</td>
  <td><strong>Tema 1.234 / Tema 6</strong> (STF)</td>
  <td>Cost threshold: ≥210 min. salaries → Federal Court. Union reimburses 65%. Financial incapacity codified.</td>
  <td>[STF Temas 1.234, 6]</td>
</tr>
<tr>
  <td>2024</td>
  <td><strong>SV 60 and 61</strong></td>
  <td>Binding: interfederative agreements, administrative exhaustion requirement before litigation</td>
  <td>[SV 60, 61]</td>
</tr>
</tbody>
</table>
<p><strong>Impact of Tema 106 on behavior:</strong> Minimal. Grant rates remained ~93%.
Citations of technical standards in decisions: &lt;6%. &quot;Supply of medicines&quot;
filings: only 4% dip in 2017–2018. Volume continued to accelerate post-2020.
[CNJ/Insper 2019]</p>
<p><strong>Early evidence on 2024 reforms (SV 60/61, Temas 1.234/6):</strong> Modest effects so
far. SUS-related lawsuits declined approximately <strong>7%</strong> in the first half of
2025, but grant rates for preliminary injunctions remain above <strong>73%</strong>.
[cnjpnud2025]</p>
<p><strong>Implication for our analysis:</strong> Pre-2024 data captures the period when (a)
municipalities bore the full fiscal cost (no reimbursement), (b) there was no
administrative exhaustion requirement, and (c) judges had maximum discretion.</p>
<hr />
<h2 id="8-venue-choice-and-forum-shopping">8. Venue Choice and Forum Shopping</h2>
<p>&lt;!-- Updated: 2026-02-06 | Sources: CPC, TJSP Súmulas, STF Tema 793 | Fully sourced --&gt;</p>
<h3 id="rules">Rules</h3>
<ul>
<li><strong>No judge-shopping:</strong> automated random assignment within each comarca.
[CPC Art. 284–285; NSCGJ]</li>
<li><strong>Comarca = plaintiff's domicile</strong> (usually). [CPC Art. 46]</li>
<li><strong>Entity-dimension forum shopping existed:</strong> plaintiffs could choose whether
to sue the municipality, state, or Union, regardless of administrative
responsibility. [CF/88 Art. 23(II); TJSP Súmula 37]</li>
<li><strong>Tema 793 (2019)</strong> partially addressed this by requiring judges to redirect
to the responsible entity. [STF Tema 793]</li>
<li><strong>TJSP Súmula 37:</strong> Health action can be filed against any public entity.
[TJSP Súm. 37]</li>
<li><strong>TJSP Súmula 29:</strong> Prohibits <em>denunciação da lide</em> (third-party practice).
[TJSP Súm. 29]</li>
</ul>
<h3 id="implications-for-identification">Implications for identification</h3>
<ul>
<li>Random assignment to judges is clean — no judge-shopping.
[CPC Art. 284–285; NSCGJ/TJSP]</li>
<li>Forum shopping on the entity dimension does not threaten identification
(it affects who pays, not which judge decides).</li>
<li>Comarca maps to municipality, supporting the case-to-municipality linkage.
[CPC Art. 46; TJSP comarca organizational data]</li>
</ul>
<hr />
<h2 id="9-key-data-sources-for-the-paper">9. Key Data Sources for the Paper</h2>
<p>&lt;!-- Updated: 2026-02-06 (Round 2) | Sources: TCE-SP, Portaria 42/1999, Ipea 2025 | Fully sourced --&gt;</p>
<table>
<thead>
<tr>
  <th>Source</th>
  <th>What it provides</th>
  <th>Coverage</th>
  <th>Access</th>
  <th>Source for claim</th>
</tr>
</thead>
<tbody>
<tr>
  <td><strong>TJSP (DataJud / Consulta)</strong></td>
  <td>Case records, judge identity, outcomes, decision text</td>
  <td>2008+ (quality varies)</td>
  <td>Public (scraped)</td>
  <td>[Our data collection]</td>
</tr>
<tr>
  <td><strong>TCE-SP (Audesp/Despesas)</strong></td>
  <td>Line-item municipal expenditures with judicial tagging in <code>historico_despesa</code></td>
  <td>2008–2024, 644 municipalities (excl. SP capital)</td>
  <td>Public (download from transparencia.tce.sp.gov.br)</td>
  <td>[Our TCE-SP exploration, Feb 2025]</td>
</tr>
<tr>
  <td><strong>SIOPS</strong></td>
  <td>Municipal health spending by subfunção (301–306)</td>
  <td>2000+, all municipalities</td>
  <td>Public (datasus.saude.gov.br)</td>
  <td>[LC 141/2012 Art. 39; standard]</td>
</tr>
<tr>
  <td><strong>DATASUS (SIM, SINASC, SIH, SIA)</strong></td>
  <td>Health outcomes: mortality, births, hospitalizations</td>
  <td>1990s+, all municipalities</td>
  <td>Public (datasus.saude.gov.br)</td>
  <td>[Standard]</td>
</tr>
<tr>
  <td><strong>TRF3</strong></td>
  <td>Federal court case records</td>
  <td>2008+</td>
  <td>Public (scraped)</td>
  <td>[Our data collection]</td>
</tr>
<tr>
  <td><strong>S-CODES (SES/SP)</strong></td>
  <td>All health claims against SP state, with drug/cost detail</td>
  <td>2009–2019+</td>
  <td>Requires formal access agreement with SES/SP</td>
  <td>[Genicolo-Martins &amp; Furquim de Azevedo 2024]</td>
</tr>
<tr>
  <td><strong>BEC</strong></td>
  <td>State-level procurement data with judicial order flag</td>
  <td>Varies</td>
  <td>Likely public (SP transparency portal)</td>
  <td>[Genicolo-Martins &amp; Furquim de Azevedo 2024]</td>
</tr>
</tbody>
</table>
<h3 id="tce-sp-spending-categories-for-crowd-out-analysis">TCE-SP spending categories for crowd-out analysis</h3>
<p>Within Função 10 (Saúde), TCE-SP reports at the subfunção level at <strong>monthly</strong>
frequency with line-item granularity. [Our TCE-SP data exploration, Feb 2025]</p>
<table>
<thead>
<tr>
  <th>Subfunção</th>
  <th>Description</th>
  <th>Role in analysis</th>
</tr>
</thead>
<tbody>
<tr>
  <td><strong>Atenção Básica</strong> (301)</td>
  <td>Primary care (ESF, UBS)</td>
  <td>Main crowd-out victim</td>
</tr>
<tr>
  <td><strong>Assistência Hospitalar e Ambulatorial</strong> (302)</td>
  <td>Hospital and outpatient</td>
  <td>Secondary care</td>
</tr>
<tr>
  <td><strong>Suporte Profilático e Terapêutico</strong> (303)</td>
  <td>Pharmaceutical, vaccines, devices</td>
  <td>Likely destination of judicial spending</td>
</tr>
<tr>
  <td><strong>Vigilância Epidemiológica</strong> (305)</td>
  <td>Disease surveillance</td>
  <td>Control</td>
</tr>
<tr>
  <td><strong>Vigilância Sanitária</strong> (304)</td>
  <td>Health inspection</td>
  <td>Control</td>
</tr>
<tr>
  <td><strong>Administração Geral</strong> (122)</td>
  <td>Admin overhead</td>
  <td>Control — <strong>caution: significant spending here due to &quot;matricialidade&quot; rules</strong></td>
</tr>
</tbody>
</table>
<p>Subfunção definitions come from Portaria 42/1999 and have been consistent since
1999. [Portaria 42/1999; Portaria 42 Classification, p. 732]</p>
<p><strong>Note on subfunção 122:</strong> Significant municipal health spending is reported
under Administração Geral due to &quot;matricialidade&quot; rules, which capture
administrative overhead of the health secretariat rather than direct care.
[Portaria 42 Classification, p. 745] This requires attention in data cleaning.</p>
<p>Judicial spending is identifiable via free-text markers in <code>historico_despesa</code>:
&quot;conforme Determinação Judicial&quot;, &quot;cumprimento de sentença&quot;, &quot;tutela
antecipada&quot;, &quot;mandado de segurança&quot;, &quot;ordem judicial&quot;, &quot;decisão judicial&quot;,
&quot;liminar&quot;. [Our TCE-SP data exploration, Feb 2025]</p>
<p><strong>SIOPS does not have a specific line item for judicially mandated spending.</strong>
Court-ordered expenditures are mixed into subfunções 302 and 303.
[Ipea 2025; our SIOPS exploration]</p>
<hr />
<h2 id="10-key-empirical-facts-for-calibration-and-motivation">10. Key Empirical Facts (for calibration and motivation)</h2>
<p>&lt;!-- Updated: 2026-02-09 | Fully sourced --&gt;</p>
<table>
<thead>
<tr>
  <th>Fact</th>
  <th>Value</th>
  <th>Source</th>
</tr>
</thead>
<tbody>
<tr>
  <td>SUS health cases filed at TJSP per year</td>
  <td>~120,000 (37% of 325k total)</td>
  <td>[Sintese Tjsp Planos Vs Sus, p. 811]</td>
</tr>
<tr>
  <td>Grant rate for SUS medication cases</td>
  <td>~93%</td>
  <td>[TJSP Sentencas Summary, p. 1364]</td>
</tr>
<tr>
  <td>Median time for preliminary injunction</td>
  <td>~10 days</td>
  <td>[Tutela Provisoria Senado, p. 1443]</td>
</tr>
<tr>
  <td>Judges handling health cases at TJSP</td>
  <td>3,006</td>
  <td>[TJSP full collapsed sentença data]</td>
</tr>
<tr>
  <td>Comarcas with health litigation</td>
  <td>322</td>
  <td>[TJSP full collapsed sentença data]</td>
</tr>
<tr>
  <td>Share of cases in SP interior (not capital)</td>
  <td>~77%</td>
  <td>[TJSP sentença data]</td>
</tr>
<tr>
  <td>Judicial drug purchase cost premium</td>
  <td>30–44%</td>
  <td>[Genicolo-Martins &amp; Furquim de Azevedo 2024]</td>
</tr>
<tr>
  <td>Total MoH judicial compliance costs (2024)</td>
  <td>R$2.7 billion</td>
  <td>[folha2025elevidys]</td>
</tr>
<tr>
  <td>Municipalities devoting 30–100% of health budget to judicial mandates (2024)</td>
  <td>270+</td>
  <td>[theconversation2024]</td>
</tr>
<tr>
  <td>Judicial share of municipal pharma budgets (avg)</td>
  <td>8.4%</td>
  <td>[Ipea Gastos Judicializacao 2025, p. 545]</td>
</tr>
<tr>
  <td>Campinas judicial pharma share (2009)</td>
  <td>16%</td>
  <td>[diniz2014csc]</td>
</tr>
<tr>
  <td>SP municipalities with tagged judicial health spending</td>
  <td>72% of sample</td>
  <td>[Our TCE-SP exploration, Feb 2025]</td>
</tr>
<tr>
  <td>Judicial health spending share range</td>
  <td>0–6.8% of health budget</td>
  <td>[Our TCE-SP exploration, Feb 2025]</td>
</tr>
<tr>
  <td>State judicial medication spending share</td>
  <td>32.9% of pharma expenditures (2023)</td>
  <td>[Ipea Gastos Judicializacao 2025, p. 545, 568]</td>
</tr>
<tr>
  <td>Union judicial medication spending</td>
  <td>R$1.9 billion (2024)</td>
  <td>[Ipea Gastos Judicializacao 2025, p. 549]</td>
</tr>
<tr>
  <td>Citation rate of technical standards in decisions (national)</td>
  <td>&lt;6%</td>
  <td>[CNJ/Insper 2019, p. 91]</td>
</tr>
<tr>
  <td>NAT-Jus citation rate at TJSP specifically</td>
  <td>0.01% (9 of 107,497)</td>
  <td>[CNJ/Insper 2019]</td>
</tr>
<tr>
  <td>Tema 106 impact on &quot;supply of medicines&quot; filings</td>
  <td>4% dip (2017–2018)</td>
  <td>[CNJ/Insper 2019]</td>
</tr>
<tr>
  <td>Appeal rate (national, 2008–2017)</td>
  <td>~55%</td>
  <td>[CNJ/Insper 2019, p. 87]</td>
</tr>
<tr>
  <td>Defensoria share of first-instance cases</td>
  <td>~7%</td>
  <td>[TJSP Sentencas Summary, p. 1364]</td>
</tr>
<tr>
  <td>Economically vulnerable litigants</td>
  <td>~20%</td>
  <td>[CNJ 2021, p. 269]</td>
</tr>
<tr>
  <td>Litigation concentration (6 lawyers)</td>
  <td>35% of state cases</td>
  <td>[TCU Orcamento Judicializacao, p. 980]</td>
</tr>
<tr>
  <td>Municipalities with administrative paths</td>
  <td>52.1%</td>
  <td>[Ipea 2025, p. 545]</td>
</tr>
<tr>
  <td>Municipal secretariats with dedicated legal units</td>
  <td>50–60%</td>
  <td>[CNJ 2021, p. 270]</td>
</tr>
<tr>
  <td>SUS exclusive reliance</td>
  <td>75% (~160M people)</td>
  <td>[castro2019lancet]</td>
</tr>
<tr>
  <td>ESF population coverage</td>
  <td>&gt;60%</td>
  <td>[macinko2006jech]</td>
</tr>
<tr>
  <td>Municipalities reporting medicine stockouts (2022)</td>
  <td>&gt;80%</td>
  <td>[cnm2022]</td>
</tr>
<tr>
  <td>Federal judicial pharma spending growth</td>
  <td>R$70M (2008) → R$1B+ (2015)</td>
  <td>[tcu2017]</td>
</tr>
<tr>
  <td>Federal judicial spending concentration (2010–2015)</td>
  <td>&gt;50% in 3 non-listed drugs</td>
  <td>[vieira2020hhr]</td>
</tr>
<tr>
  <td>Non-registered drug judicial spending</td>
  <td>R$2.4M (2010) → R$545M (2015)</td>
  <td>[cambricoli2016estadao]</td>
</tr>
<tr>
  <td>Fiscal mismatch: SP judicial pharma from other levels</td>
  <td>55%</td>
  <td>[wang2014rap]</td>
</tr>
<tr>
  <td>Defensoria absent from comarcas (2013)</td>
  <td>72%</td>
  <td>[ipea_anadep2013]</td>
</tr>
<tr>
  <td>On-formulary share of medication lawsuits</td>
  <td>&gt;50%</td>
  <td>[biehl2009lancet; chieffi2009csp]</td>
</tr>
<tr>
  <td>Post-2024 reform: SUS lawsuit decline (H1 2025)</td>
  <td>~7%</td>
  <td>[cnjpnud2025]</td>
</tr>
<tr>
  <td>Post-2024 reform: preliminary injunction grant rate</td>
  <td>&gt;73%</td>
  <td>[cnjpnud2025]</td>
</tr>
</tbody>
</table>
<hr />
<h2 id="references-cited-in-this-document">References cited in this document</h2>
<ul>
<li>Biehl, J., Petryna, A., Gertner, A., Amon, J. J., &amp; Picon, P. D. (2012). Judicialisation of the right to health in Brazil. <em>The Lancet</em>, 373(9682), 2182–2184.</li>
<li>CF/88: Constituição da República Federativa do Brasil de 1988.</li>
<li>Chieffi, A. L., &amp; Barata, R. B. (2009). Judicialização da política pública de assistência farmacêutica e equidade. <em>Cadernos de Saúde Pública</em>, 25(8), 1839–1849.</li>
<li>CNJ Resolution 238/2016: Resolução nº 238, de 6 de setembro de 2016.</li>
<li>CNJ/Insper (2019): Judicialização da Saúde no Brasil: Perfil das demandas, causas e propostas de solução.</li>
<li>CPC: Código de Processo Civil (Lei 13.105/2015).</li>
<li>EC 29/2000: Emenda Constitucional nº 29, de 13 de setembro de 2000.</li>
<li>Genicolo-Martins, V. H., &amp; Furquim de Azevedo, P. (2024). [Working paper on judicial procurement costs in SP].</li>
<li>LC 141/2012: Lei Complementar nº 141, de 13 de janeiro de 2012.</li>
<li>Lei 8.080/1990: Lei Orgânica da Saúde.</li>
<li>Lei 12.401/2011: Altera a Lei 8.080 para dispor sobre assistência terapêutica e incorporação de tecnologia em saúde.</li>
<li>NSCGJ: Normas de Serviço da Corregedoria Geral da Justiça do TJSP.</li>
<li>Portaria 42/1999: Portaria MOG nº 42, de 14 de abril de 1999 (functional classification of expenditures).</li>
<li>STF Tema 6, Tema 500, Tema 793, Tema 1.234: Binding precedents of the Supremo Tribunal Federal.</li>
<li>STJ Tema 106 (REsp 1.657.156/RJ): Binding precedent of the Superior Tribunal de Justiça.</li>
<li>SV 60, SV 61: Súmulas Vinculantes 60 and 61 of the STF (2024).</li>
<li>CNJ (2021): Judicialização e Sociedade: Ações para Acesso à Saúde Pública de Qualidade.</li>
<li>CONASS/BVS (2018): Coleção Para Entender a Gestão do SUS — Assistência Farmacêutica no SUS.</li>
<li>Fiocruz (2020): A Judicialização da Saúde nos Municípios Brasileiros.</li>
<li>Ipea (2025): Gastos com Judicialização da Saúde no Brasil.</li>
<li>STJ Tema 84: Bloqueio de verbas públicas para cumprimento de obrigação de fazer em saúde.</li>
<li>STJ Tema 98: Multa diária contra a Fazenda Pública.</li>
<li>TCU: Relatório de Orçamento e Judicialização da Saúde.</li>
<li>TJSP Caderno de Judicialização da Saúde (2024).</li>
<li>Tutela Provisória — Senado Federal (análise).</li>
<li>Wang, D. W. L., &amp; Ferraz, O. L. M. (2013). Reaching out to the needy? Access to justice and public attorneys' role in right to health litigation in the city of São Paulo. <em>SUR International Journal on Human Rights</em>, 10(18), 159–179.</li>
<li>Wang, D. W. L. (2014). Poder Judiciário e participação democrática nas políticas de saúde. <em>Revista de Administração Pública</em> (RAP).</li>
<li>Wang, D. W. L. (2015). Right to health litigation in a social inequality context. <em>Health Economics, Policy and Law</em>.</li>
<li>Biehl, J., &amp; Petryna, A. (2009). Bodies of rights and therapeutic markets. <em>The Lancet</em>, 374(9698), 1437–1439.</li>
<li>Biehl, J., Socal, M. P., &amp; Amon, J. J. (2016). The judicialization of health and the quest for state accountability. <em>Health and Human Rights</em>, 18(1), 209–220.</li>
<li>Castro, M. C., et al. (2019). Brazil's unified health system: the first 30 years and prospects for the future. <em>The Lancet</em>, 394(10195), 345–356.</li>
<li>CFM (2024). Conselho Federal de Medicina — estimate of elective procedure backlog.</li>
<li>CGU (2021). Auditoria sobre disponibilização de medicamentos incorporados pelo CONITEC.</li>
<li>CNM (2022). Confederação Nacional de Municípios — survey on medication stockouts.</li>
<li>CNJ/PNUD (2025). Early evidence on SV 60/61 and Tema 1.234/6 reform effects.</li>
<li>Cambricoli, F. (2016). <em>O Estado de São Paulo</em> — reporting on non-registered drug spending growth.</li>
<li>Diniz, D., et al. (2014). Judicialização da saúde no Distrito Federal. <em>Ciência &amp; Saúde Coletiva</em>, 19(2), 591–598.</li>
<li>Folha de S. Paulo (2025). Reporting on medicine incorporation delays.</li>
<li>Folha de S. Paulo (2025, &quot;Elevidys&quot;). Total MoH judicial compliance costs R$2.7B.</li>
<li>IPEA/ANADEP (2013). Mapa da Defensoria Pública no Brasil.</li>
<li>Macinko, J., et al. (2006). Evaluation of the Family Health Program in Brazil. <em>Journal of Epidemiology &amp; Community Health</em>, 60(1), 13–19.</li>
<li>STF Pet 1246-SC (1997). Landmark decision on individual right to health.</li>
<li>TCU (2017). Relatório de auditoria sobre judicialização da saúde.</li>
<li>The Conversation (2024). Reporting on municipalities devoting 30–100% of health budgets to judicial mandates.</li>
<li>Vieira, F. S. (2020). Direito à saúde e judicialização. <em>Health and Human Rights</em>.</li>
</ul>

</div>
</main>

<footer>
  Generated by <code>bash build.sh site</code>
</footer>

<script>
document.addEventListener('DOMContentLoaded', () => {
  const body = document.querySelector('.md-body');
  if (!body) return;

  function foldHeadings(container, tag) {
    const level = tag.replace('H', '');
    const headings = Array.from(container.querySelectorAll(':scope > ' + tag.toLowerCase()));
    headings.forEach(h => {
      const details = document.createElement('details');
      details.className = 'level-' + level;
      if (h.id) details.id = h.id;
      const summary = document.createElement('summary');
      summary.innerHTML = h.innerHTML;
      details.appendChild(summary);
      let sibling = h.nextElementSibling;
      const collected = [];
      while (sibling && sibling.tagName !== tag) {
        collected.push(sibling);
        sibling = sibling.nextElementSibling;
      }
      collected.forEach(el => details.appendChild(el));
      h.replaceWith(details);
    });
    return headings.length;
  }

  // Fold h2 sections, then h3 sections within each h2
  const count = foldHeadings(body, 'H2');
  if (count === 0) {
    document.querySelector('.doc-controls').style.display = 'none';
    return;
  }
  body.querySelectorAll('details.level-2').forEach(d => foldHeadings(d, 'H3'));

  // Toggle button
  const btn = document.getElementById('toggle-sections');
  if (!btn) return;
  btn.addEventListener('click', () => {
    const allDetails = body.querySelectorAll('details');
    const expanding = btn.textContent === 'Expand all';
    allDetails.forEach(d => d.open = expanding);
    btn.textContent = expanding ? 'Collapse all' : 'Expand all';
  });

  // Auto-open details when navigating to an anchor
  function openAnchorTarget() {
    if (!location.hash) return;
    const target = document.querySelector(location.hash);
    if (!target) return;
    let el = target;
    while (el) {
      if (el.tagName === 'DETAILS') el.open = true;
      el = el.parentElement;
    }
    target.scrollIntoView();
  }
  openAnchorTarget();
  window.addEventListener('hashchange', openAnchorTarget);
});
</script>

</body>
</html>
